Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.03, Briefing.com reports. The company had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period last year, the company posted ($0.36) EPS.
Nektar Therapeutics (NASDAQ NKTR) traded down 3.01% during mid-day trading on Tuesday, hitting $19.64. The company’s stock had a trading volume of 956,445 shares. The stock’s market cap is $3.05 billion. The company’s 50 day moving average is $20.53 and its 200-day moving average is $18.09. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $24.88.
TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NASDAQ:NKTR) Issues Earnings Results, Misses Expectations By $0.03 EPS” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/08/08/nektar-therapeutics-nasdaqnktr-issues-earnings-results-misses-expectations-by-0-03-eps.html.
A number of analysts recently issued reports on the company. Jefferies Group LLC reissued a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, July 21st. Piper Jaffray Companies reissued an “overweight” rating and set a $29.00 price objective on shares of Nektar Therapeutics in a report on Tuesday, April 11th. Aegis reissued a “buy” rating and set a $27.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, May 10th. BidaskClub cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $26.56.
In other news, SVP Ivan P. Gergel sold 54,920 shares of the company’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total value of $1,158,812.00. Following the completion of the transaction, the senior vice president now owns 98,492 shares of the company’s stock, valued at $2,078,181.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 1,701 shares of the company’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $19.55, for a total value of $33,254.55. Following the completion of the transaction, the senior vice president now directly owns 32,803 shares of the company’s stock, valued at approximately $641,298.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 159,803 shares of company stock valued at $3,328,247. Corporate insiders own 5.44% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
